In the world of science PR, it's not enough to have groundbreaking research – you need a story that grips. A narrative that not only informs but also intrigues. So how do you break through the clutter and make your science news sing?

CureLab Oncology’s DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer.

The clinical benefits currently delivered for terminally ill patients in CureLab’s clinical trial are already exceeding the benefits of new drugs recently approved by the FDA.

“… when Elenagen was added to the treatment regimen, all patients showed complete or partial regression of the primary tumor and associated metastases in the lungs, liver, lymph nodes, and bones.”

This latest patent makes it feasible for CureLab to commence clinical trials aimed at establishing the effectiveness of Elenagen™ and its product variations for treatment of several deadly neurodegenerative diseases.

CureLab Oncology forms veterinary oncology subsidiary to fight pet cancer—and gain valuable insights into the mechanism of its Elenagen™ gene therapy

The pre-IND briefing package was centered around a proposed Phase II US clinical trial for CureLab’s experimental cancer-fighting DNA vaccine.

CureLab is developing an investigational DNA vaccine called Elenagen, which reverses tumor grade, changes tumor microenvironment, and stimulates an immune attack on the tumor.